When OHTC was founded, only one treatment — plasma — was available to replace the missing or deficient clotting factors. Every patient, regardless of the type of bleeding disorder, received it. Because plasma sometimes caused allergic reactions, patients were infused only at OHTC.
By the mid-1960s, fractionation of plasma into its various protein components led to development of clotting-factor concentrates, each type specific for the deficiency of one clotting factor but not another. Concentrates led to profound changes in the management of hemophilia. As allergic reactions became rare in the early 1970s, patients could be trained to treat themselves at home.
Today, self-infusion means that hemorrhages are treated earlier, before damage occurs. It also means that patients miss less school or work, and families are free to plan vacations and have control over their lives. Patients whose lives had been tethered to a hospital or clinic a generation ago can now expand their horizons, live more normal lives and move confidently in the world.
Today, self infusion is common, but OHTC remains available for patients who prefer onsite services.